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While numerous cell-intrinsic processes are known
to play decisive roles in chemotherapeutic response,
relatively little is known about the impact of the tumor
microenvironment on therapeutic outcome. Here, we
use a well-established mouse model of Burkitt’s
lymphoma to show that paracrine factors in the
tumor microenvironment modulate lymphoma cell
survival following the administration of genotoxic
chemotherapy. Specifically, IL-6 and Timp-1 are
released in the thymus in response to DNA damage,
creating a ‘‘chemo-resistant niche’’ that promotes
the survival of a minimal residual tumor burden and
serves as a reservoir for eventual tumor relapse.
Notably, IL-6 is released acutely from thymic endo-
thelial cells in a p38-dependent manner following
genotoxic stress, and this acute secretory response
precedes the gradual induction of senescence in
tumor-associated stromal cells. Thus, conventional
chemotherapies can induce tumor regression while
simultaneously eliciting stress responses that pro-
tect subsets of tumor cells in select anatomical loca-
tions from drug action.
INTRODUCTION
While significant progress has been made in the application of
chemotherapy over the past 40 years, most chemotherapeutic
regimens ultimately fail to cure cancer patients (Holen and Saltz,
2001). Even tumors that show dramatic initial responses to
therapy frequently relapse as chemoresistant malignancies.
This chemoresistance is thought to arise as a consequence of
cell intrinsic genetic changes including upregulation of drug
efflux pumps, activation of detoxifying enzymes or apoptotic
defects (Bleau et al., 2009). However, recent data suggests
that resistance to chemotherapy can also result from cell
extrinsic factors such as cytokines and growth factors (Eckstein
et al., 2009;Williams et al., 2007). Additionally, other studies have
suggested that rare cancer stem cells are the source of eventual
tumor relapse following therapy, as these cells are thought to be
drug resistant due to increased genomic stability, decreased
oxidative stress or the presence of multiple drug resistance
transporters (Visvader and Lindeman, 2008).Modern combinatorial chemotherapeutic regimes can reduce
patient tumor burdens to undetectable levels, yet in many cases
these tumors will relapse (Corradini et al., 1999). Thus, even
when a patient is classified as being in complete remission,
surviving cancer cells can persist in particular anatomical
locations. This remnant population of cancer cells has been
described as minimal residual disease (MRD). MRD is generally
not macroscopic andmay not be at the site of the primary tumor,
making this phenomenon difficult to dissect experimentally
(Ignatiadis et al., 2008). While MRD is a significant clinical
problem, few models exist to study residual tumor burden
following therapy. Thus, it remains unclear whether the cancer
cells that compose the MRD burden are surviving following
chemotherapy due to stochastic events, intrinsic drug resis-
tance, or microenvironmental cues.
Efforts to experimentally recapitulate the response of human
tumors in vivo to chemotherapy have generally relied upon xeno-
grafts of human tumors transplanted into immunodeficient mice
(Sharpless and Depinho, 2006). These models have proven inef-
fective in predicting drug efficacy, likely due to a failure to repro-
duce the complexity of a tumor with its associated complement
of stromal, immune and endothelial cells. This autochthonous
tumor microenvironment includes a complex mixture of pro-
and antineoplastic factors (Hideshima et al., 2007). Both malig-
nant and untransformed cells within a tumor influence the
balance of growth factors, chemokines and cytokines found in
the tumor microenvironment. These factors play key roles in
regulating tumor cell proliferation, and survival through the acti-
vation of diverse signaling pathways, including the Jak/Stat,
NFkB, Smad, and PI3K pathways (Nguyen et al., 2009).
While numerous studies have addressed the role of tumor-
proximal factors in tumor growth or metastasis, relatively few
have addressed the role of the tumor microenvironment in
chemotherapeutic outcome (Hanahan and Weinberg, 2000).
Here we show that two cytokines, IL-6 and Timp-1, protect
lymphoma cells from cell death induced by genotoxic chemo-
therapy, such that small molecule inhibition of cytokine-induced
signaling potentiates chemotherapeutic efficacy. We further
show that IL-6 release occurs as a result of p38 MAP Kinase
activation in tumor-associated endothelial cells acutely follow-
ing DNA damage. This acute cytokine release also occurs in
treated human endothelial and hepatocellular carcinoma
cells, suggesting that acute secretory responses may occur in
numerous contexts. In the thymus, rapid cytokine release
precedes the induction of senescence – a process recently
shown to promote sustained cytokine release in cultured cellsCell 143, 355–366, October 29, 2010 ª2010 Elsevier Inc. 355
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Figure 1. The ThymusRepresents aChemo-
protective Niche that Harbors Surviving
Lymphoma Cells Following Doxorubicin
Treatment
(A) Lymphoma-bearing mice were imaged for
whole body fluorescence prior to treatment and
4 days following a single dose of 10mg/kg doxoru-
bicin. Representative mice are shown.
(B) Ratios of live GFP-tagged Em-myc p19Arf/ B
lymphoma cells in the thymus versus peripheral
lymph nodes were quantified by flow cytometry,
before (n = 4 mice) and 48 hr after (n = 5 mice)
doxorubicin treatment. Average ratios are indi-
cated with a line.
(C) Hematoxylin and eosin (H&E) sections of lymph
node and thymus from a tumor-bearing bearing
mouse 48 hr after doxorubicin treatment. The
dotted line in the thymus demarcates a small
region of infiltrating lymphocytes neighboring
a larger region of surviving lymphoma cells.
Representative fields are shown at 403magnifica-
tion.
(D) A western blot showing g-H2AX levels in FACS
sorted GFP-positive lymphoma cells from the
thymus and peripheral lymph nodes following
doxorubicin treatment. b-Tubulin serves as a
loading control. The untreated sample is a lysate
from cultured lymphoma cells.
(E) A Kaplan-Meier curve showing the overall
survival of tumor-bearing C57BL/6 (n = 8) or
C57BL/6 Rag1/ (n = 5) mice following doxoru-
bicin treatment. The p value was calculated using
a log rank test.
See also Figure S1.(Acosta et al., 2008; Coppe et al., 2008; Kuilman et al., 2008;
Wajapeyee et al., 2008). Thus, genotoxic drugs can, paradoxi-
cally, elicit prosurvival signaling in select anatomical sites,
providing a reservoir of minimal residual disease that subse-
quently fuels tumor relapse.
RESULTS
The Thymus Represents a Chemoprotective
Tumor Microenvironment
To investigate the dynamics of lymphoma response and relapse
following chemotherapy, we used a well-established preclinical
model of human Burkitt’s lymphoma—the Em-myc mouse
(Adams et al., 1985). Tumors from these mice can be trans-
planted into immunocompetent syngeneic recipient mice, and
the resulting tumors are pathologically indistinguishable from
autochthonous tumors (Burgess et al., 2008). Six to 8 week old
mice were tail vein injected with GFP-tagged Em-myc p19Arf/
B lymphoma cells. At tumor onset all mice displayed a character-
istic disseminated pattern of disease with lymphoma cells in the
peripheral lymph nodes, spleen and mediastinum. Mice were356 Cell 143, 355–366, October 29, 2010 ª2010 Elsevier Inc.treated with the maximum tolerated dose of the front-line
chemotherapeutic doxorubicin at the time of lymphoma mani-
festation. Three days after administration of doxorubicin, all
mice displayed tumor regression and peripheral tumor clear-
ance, measured by lymph node palpation. These mice were
sacrificed at four days posttreatment and sites of minimal
residual disease were identified by GFP imaging. Interestingly,
the majority of surviving lymphoma cells were in the mediastinal
cavity (Figure 1A), a central component of the thoracic cavity that
encapsulates the heart, esophagus, trachea and a large amount
of lymphatic tissue including the mediastinal lymph nodes and
the thymus.
To analyze the effect of drug treatment on specific tumor
niches, we harvested all primary lymphoid organs, including
peripheral lymph nodes, thymus, spleen and bone marrow,
following doxorubicin treatment. All tissues sampled showed
extensive lymphoma cell apoptosis and restoration of normal
organ architecture. Peripheral lymph nodes, spleen and bone
marrow exhibited nearly complete tumor clearance with rare
surviving lymphoma cells (Figure 1C and Figure S1A available
online). In contrast, many surviving B lymphoma cells could
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Figure 2. Thymic Conditioned Media Contains Soluble
Chemoprotective Factors
(A) A graph showing lymphoma cell survival in the presence of
doxorubicin alone or in the presence of conditionedmedia. The
data are represented as mean ± standard error of the mean
(SEM) (n = 3).
(B) A graph showing the growth of lymphoma cells cultured in
the absence or presence of conditioned media. The data are
represented as mean ± SEM (n = 3).
(C) Cytokine array analysis of conditioned media from
untreated and doxorubicin treated lymph nodes and thymus.
The data is represented graphically as normalized signal inten-
sity. Conditioned media was pooled from 3 or 4 mice for each
array.be seen in the thymus. To quantify this phenotype, cells were
harvested from peripheral lymph nodes and the thymus
following treatment, and the number of surviving GFP positive
lymphoma cells was assessed by flow cytometry. The number
of viable lymphoma cells in the thymus relative to the lymph
nodes increased 6.5-fold following doxorubicin treatment
(Figure 1B). Thus, the thymus represents a chemoprotective
niche that protects lymphoma cells from doxorubicin-induced
cell death.
To rule out the possibility that the selective survival of tumor
cells in the thymus was due to the specific exclusion of doxoru-
bicin from the mediastinum, we sorted live GFP-positive tumor
cells from the lymph nodes and thymus 12 hr after doxorubicin
treatment and blotted for g-H2AX, a marker of DNA damage
(Morrison and Shen, 2005). Western blot analysis showed that
cells in both anatomical locations undergo the same amount of
DNA damage (Figure 1D). Additionally, flow cytometry of medi-
astinal lymphoma cells failed to identify any sub-population of
lymphoma cells with decreased g-H2AX fluorescence
(Figure S1B). These data suggest that the thymus offers no phys-
ical barrier to drug delivery.
Minimal Residual Tumor Burden in the Thymus Fuels
Tumor Relapse Following Chemotherapy
Given the persistence of tumor cells in the thymus following
chemotherapy, we next sought to determine whether tumor cells
in the thymus contributed to lymphoma relapse. To this end, weCell 143examined therapeutic response in genetically
and surgically athymic mice. We injected control
or Rag1 deficient mice, which have severely atro-
phic thymuses, with lymphoma cells and then
treated tumor-bearing recipient animals with
doxorubicin. Overall survival and tumor free
survival were significantly extended in tumor-
bearing Rag1 deficient mice, relative to control
animals, suggesting that the presence of a func-
tional thymus promotes relapse and disease
progression (Figure 1E and Figure S1C). Similarly,
surgically thymectomized tumor-bearing mice also
showed extended tumor-free and overall survival
following therapy relative to control animals
(Figure S1D and data not shown). Notably, overallsurvival in untreated tumor-bearing Rag1 deficient or thymec-
tomized mice was indistinguishable from that in control
animals (Figure S1E). Thus, the thymus harbors minimal residual
disease that contributes to tumor relapse following therapy in
this model.
Cultured Thymuses Secrete Prosurvival Factors In Vitro
Preferential lymphoma cell survival in the thymus following doxo-
rubicin treatment suggests that specific anatomical microenvi-
ronments may contain prosurvival factors absent in other
lymphoid organs. There is precedence for this phenomenon in
multiple myeloma, where the bone marrow microenvironment
promotes myeloma cell survival (Hideshima et al., 2007). To
address this possibility, we derived conditioned media from
the thymus (TM, for thymic media), bone marrow (BMM) and
lymph nodes (LNM) of mice treated with doxorubicin. Cultured
lymphoma cells were then treated with doxorubicin, along with
TM, LNM or BMM. Addition of TM provided a significant survival
advantage, with 10-fold more cells surviving 48 hr following
treatment (Figure 2A). This effect was specifically prosurvival,
as opposed to proproliferative, as these same conditioned
medias had little effect on lymphoma cell growth (Figure 2B). In
contrast, conditioned media derived from peripheral lymph
nodes had only a minimal effect on lymphoma cell survival (Fig-
ure 2A). Thus, soluble prosurvival factor(s) present in the thymic
microenvironment protect tumor cells from genotoxic chemo-
therapy., 355–366, October 29, 2010 ª2010 Elsevier Inc. 357
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Figure 3. IL-6 and Timp-1 Are Chemopro-
tective In Vitro and In Vivo
(A) A graph showing the fold change in lymphoma
cell number 72 hr after treatment with doxorubicin
as a single agent or doxorubicin plus recombinant
IL-6. The data are represented as mean ± SEM
(n = 4 independent experiments).
(B) A graph showing the relative survival of cultured
lymphoma cells at 24 hr intervals following treat-
ment with doxorubicin alone, doxorubicin plus
recombinant IL-6 or Timp-1, or doxorubicin plus
both IL-6 and Timp-1. The data are represented
as mean ± SEM (n = 3 independent experiments).
(C) A schematic diagram of the lymphoma trans-
plant experiment, showing injection of IL-6+/+
lymphoma cells into both IL-6+/+ and IL-6/ recip-
ients.
(D) A Kaplan-Meier curve showing post-treatment
survival of IL-6+/+ (n = 17) or IL-6/ (n = 5) mice
bearing IL-6+/+ lymphomas. All mice were treated
with a single dose of 10mg/kg doxorubicin. The
p value was calculated using a log rank test.
(E) H&E stained sections of lymphomas 72 hr
following doxorubicin treatment. The black dotted
line shown in the thymus from the IL-6+/+ recipient
mouse demarcates a zone of surviving lymphoma
cells that is absent in the other sections. Repre-
sentative fields are shown at 203 magnification.
See also Figure S2.Cytokine Levels Vary between Tumor-Bearing
Anatomical Locations
To identify the factor(s) contributing to lymphoma cell survival in
the thymus, we performed cytokine arrays analyzing the abun-
dance of 40 cytokines and chemokines in conditioned media
from doxorubicin treated and untreated tumors (Figure 2C and
data not shown). Analysis of cytokine expression showed
significant differences between the thymic and lymph node
tumor microenvironments. Multiple factors related to cell
migration and cell cycle control were acutely upregulated
in thymic lymphomas, but not in peripheral lymphomas or
cultured lymphoma cells, following doxorubicin treatment.
These included the cytokines G-CSF, IL-1a, IL-1ra, IL-6, IL-16,
and the chemokines and growth factors KC, MCP-1, MCP-5,
MIP-2, and Timp-1 (Figure 2C).
Each of the upregulated factors was tested in vitro for the
ability to promote doxorubicin resistance. Of the 10 recombinant
proteins examined, only two produced a significant effect
on lymphoma cell survival following doxorubicin treatment
in vitro. Recombinant Interleukin-6 (IL-6), as a single agent,
was able to promote a 2.8-fold increase in the number of
surviving lymphoma cells 72 hr following doxorubicin treatment
(Figure 3A and Figure S2A). Similarly, addition of Tissue inhibitor
of metalloproteases 1 (Timp-1) resulted in a 3-fold increase in
surviving lymphoma cells following doxorubicin treatment
(Figure 3B). These factors had a combinatorial effect (Figure 3B),
as addition of both recombinant IL-6 and Timp-1 resulted in
a 4.5-fold increase lymphoma cell number following treatment
(Figure 3B). Importantly, neither factor alone or in combination358 Cell 143, 355–366, October 29, 2010 ª2010 Elsevier Inc.affected lymphoma cell growth, suggesting that this increase in
cell number was not due to enhanced cell proliferation
(Figure S2B). Additionally, recombinant IL-6 had no effect on
lymphoma cell motility in this setting (Figure S2C).
While these data show that both Timp-1 and IL-6 promote
chemoresistance in the thymus, we decided to focus our
efforts on the contribution of IL-6 to therapeutic response.
To determine whether IL-6 was acting to promote cell survival
in an autocrine fashion following release from lymphoma cells
or a paracrine fashion following release from surrounding
thymic cells, we performed lymphoma transplant experiments
in the presence or absence of IL-6. Specifically, IL-6+/+
lymphomas were transplanted into IL-6+/+ or IL-6/ mice
(Figure 3C and Figure S2D). Tumor-bearing recipient mice
were then treated with the maximum tolerated dose of doxo-
rubicin and monitored for tumor free survival and overall
survival. Notably, while IL-6/ and IL-6+/+ recipient mice
developed pathologically indistinguishable tumors, IL-6/
recipients displayed significantly longer tumor free survival
and overall survival following treatment than their IL-6+/+ coun-
terparts (Figure 3D and Figures S2F and S2G). Additionally,
histological analysis confirmed the lack of surviving lymphoma
cells in the thymus of IL-6/ mice following treatment
(Figure 3E). Thus, IL-6 release from the tumor microenviron-
ment, rather than from the tumor itself, promotes tumor cell
survival.
To further interrogate the source of thymic IL-6, IL-6 levels
were examined in thymic lymphomas from doxorubicin-treated
IL-6+/+ and IL-6/ recipient mice, as well as doxorubicin treated
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p<0.01 p<0.05 Figure 4. Doxorubicin Induces the Release
of IL-6, and Inhibition of This Cytokine
Signaling Sensitizes Tumor Cells to Chemo-
therapy
(A) Quantification of IL-6 levels in conditioned
media from the thymus or lymph nodes of
untreated mice (n R 10) or mice treated for 18 hr
with 10mg/kg doxorubicin (n R 7). Values were
normalized by tissue weight. The data are repre-
sented as mean ± SEM.
(B) Quantification of IL-6 levels in conditioned
media derived from tumor-bearing thymuses or
lymph nodes of doxorubicin treated (n = 3) or
untreated (n = 3) mice. The data are represented
as mean ± SEM.
(C) A bar graph showing the fold change in number
of live cells at 48 hr following treatment with doxo-
rubicin alone or in combination with conditioned
media plus or minus a Jak2 inhibitor. The data
are represented as mean ± SEM (n = 3).
(D) A Kaplan-Meier curve showing tumor free
survival of lymphoma-bearing mice treated with
doxorubicin (n = 9) or doxorubicin plus two doses
of 50mg/kg AG-490 m-CF3 (n = 4). The p value
was calculated using a log rank test.
(E) H&E sections of lymphomas 72 hr after treat-
ment with doxorubicin or doxorubicin plus AG-
490m-CF3. Black dotted lines distinguish surviving
lymphoma cells, which are largely absent in the
presence of AG-490 m-CF3, from infiltrating
immune cells. Representative fields are shown at
203 magnification.
See also Figure S3.lymphoma cells in vitro (Figure 3C). No IL-6 was detected in
either IL-6+/+ lymphoma cells in vitro or in thymic or peripheral
tumors from IL-6/ lymphoma-bearing mice (data not shown).
This result strongly suggests that the IL-6 present in the tumor
microenvironment following genotoxic stress is secreted in
a paracrine manner from resident thymic cells.
Genotoxic Chemotherapy Induces the Release
of Prosurvival Cytokines In Vivo
Recent work has shown that DNA damage can induce a secre-
tory phenotype in cultured cells (Rodier et al., 2009). To deter-
mine whether IL-6 is similarly induced as a consequence of
genotoxic chemotherapy in vivo, we treated mice lacking
tumors with the maximally tolerated dose of doxorubicin.
18 hr later we assayed IL-6 levels by ELISA in untreated and
doxorubicin treated mice. As suggested by the cytokine arrayCell 143, 355–366data, IL-6 was present at a constitutively
higher level in the thymus versus the
lymph nodes of mice (Figure 4A). Addi-
tionally, doxorubicin treatment signifi-
cantly increased the amount of IL-6 in
the thymus but not in peripheral lymph
nodes or the spleen (Figure 4A and
Figure S3A). Thus, genotoxic chemo-
therapy induces a stress response in
the thymus that includes the release ofIL-6, a prosurvival cytokine. Notably, IL-6 induction in the
thymus occurred within 18 hr of treatment, much more acutely
than has been reported for secretory phenotypes in cultured
cells (Rodier et al., 2009).
To confirm that this acute DNA damage-induced secretory
response also occurs in thymuses with substantial lymphoma
infiltration, we examined IL-6 levels in tumor-bearing mice.
Again, IL-6 was constitutively present at a higher level in the
thymic tumor microenvironment versus the peripheral tumor
microenvironment, and treatment with doxorubicin resulted in
a rapid and significant increase in IL-6 levels in thymic
lymphomas but not in peripheral lymphomas (Figure 4B). As
chemotherapy rapidly induces apoptosis in lymphoid malignan-
cies, these data are consistent with the idea that acute cytokine
release following DNA-damage may directly impact therapeutic
response., October 29, 2010 ª2010 Elsevier Inc. 359
Jak2 Signaling Is Required for Lymphoma Cell Survival
Following Doxorubicin Treatment In Vivo and In Vitro
Both IL-6 and Timp-1 have been shown to signal through
Jak2 and Stat3 (Heinrich et al., 1998; Lambert et al., 2003), sug-
gesting that doxorubicin efficacy could be potentiated if Jak
signaling were chemically inhibited. We tested this hypothesis
by treating lymphoma cells with doxorubicin and TM or doxoru-
bicin and TM plus a Jak2/Jak3 inhibitor. Addition of the Jak
inhibitor completely ablated the protective effect of TM (Fig-
ure 4C). Importantly, the Jak inhibitor had a minimal effect on
lymphoma cell growth in the presence of TM (data not shown).
Thus, Jak2/Jak3 signaling promotes the chemoprotective effect
of TM in vitro.
To determine whether this effect could be recapitulated
in vivo, we treated lymphoma-bearing mice with either doxoru-
bicin, Ag490 (a Jak2/3 inhibitor previously used in murine
in vivo studies) (Gu et al., 2005), or with a combination of both
doxorubicin and Ag490. Mice treated with doxorubicin and
Ag490 showed significantly longer tumor-free survival and over-
all survival than mice treated with doxorubicin alone (Figure 4D
and Figures S3B and S3C). Histological analysis of the thymus
in mice treated with both drugs showed few surviving lymphoma
cells, in sharp contrast with those treated with doxorubicin alone
(Figure 4E). Importantly, this was not due to a simple additive
effect of doxorubicin and Ag490-induced cytotoxicity, as mice
treated with Ag490 alone exhibited no tumor free survival or
extended overall survival when compared to mice treated with
a vehicle control (Figures S3D and data not shown). Thus,
Jak2/Jak3 inhibition can eliminate prosurvival signaling in the
thymic niche and potentiate doxorubicin cytotoxicity.
IL-6 Is Released from Thymic Endothelial Cells
To identify the cell type(s) responsible for IL-6 release from the
thymic stroma, we disassociated thymuses from untreated
mice and sorted known resident cells by characteristic surface
markers. Sorted cells were then plated in normal growth media,
and IL-6 levels were assessed after 48 hr. Notably, the vast
majority of IL-6 secreted following thymic disassociation was
released from thymic endothelial cells, while B, T, dendritic,
and thymic epithelial cells failed to produce any IL-6 levels above
background (Figure 5A). Resident macrophages produced trace
levels of IL-6 (Figure 5A and Figure S4). However, they did so at
a level that was more than ten-fold less than endothelial cells.
Similar results were seen for Timp-1, which was released almost
exclusively from thymic endothelial cells (Figure 5B).
Importantly, in mice treated with doxorubicin, IL-6 levels were
significantly induced in thymic endothelial cells (Figure 5F). While
IL-6 levels were also elevated in treated macrophages (Figures
S4A), this increase was not significant and represented less
than one tenth of the amount released from treated endothelial
cells - even when adjusted for total cell number. Additionally, no
significant increase in infiltrating macrophages or dendritic cells
was seen acutely following treatment (data not shown). Consis-
tent with the central role of endothelial cells in this secretory
response, pretreatment of mice with an inhibitor of VEGFR1/2 –
receptors necessary for endothelial cell proliferation - partially
inhibited doxorubicin-induced IL-6 release (Figure S4B). These
data indicate that residentendothelial cells are largely responsible360 Cell 143, 355–366, October 29, 2010 ª2010 Elsevier Inc.for the accumulation of prosurvival factors following chemo-
therapy in thismodel. Todirectly assess the relevanceof endothe-
lial cells to tumor cell survival, we co-cultured purified endothelial
cells and lymphoma cells in the presence of doxorubicin (Fig-
ure 5C). The presence of endothelial cells dramatically increased
lymphoma cell survival following treatment, with a 15-fold
increase in lymphoma cell number in co-cultured populations
relative to lymphoma cell-only populations 72 hr posttreatment.
Several studies have indicated that cytokines, including IL-6,
may exert a prosurvival benefit in target cells through induction
of antiapoptotic Bcl2 family members, including Bcl2, Bcl-XL
and Mcl-1 (Jourdan et al., 2000). Thus, we examined the protein
levels of Bcl2 family members in lymphoma cells treated with
thymic conditioned media. While Bcl2 and Mcl-1 levels were
unaffected (data not shown), Bcl-XL was consistently induced
2- to 4-fold (Figure 5D). To further examine whether Bcl-XL
contributes to cell survival in this context, we treated cells ex-
pressing a Bcl-XL shRNA with doxorubicin alone or doxorubicin
plus IL-6 (Figure 5E). Suppression of Bcl-XL blocked the ability of
IL-6 to promote doxorubicin resistance, suggesting that IL-6
mediated induction of Bcl-XL may be necessary for its role in
cell survival. This does not, however, preclude that other factors
may contribute to cell survival following exposure to IL-6, as
cytokines are known to activate numerous prosurvival pathways.
IL-6 Release from Endothelial Cells Is Dependent
upon p38 MAP Kinase Activity
The p38 MAP Kinase (p38) is known to be a key regulator of the
expression of inflammatory cytokines, including IL-6 (Medzhitov
and Horng, 2009). To determine whether p38 is required for DNA
damage-induced IL-6 release, treated and untreated thymic
endothelial cells were purified and probed by immunofluores-
cence for the presence of activated p38. Notably, treated endo-
thelial cells showed significantly higher phospho-p38 levels than
their untreated counterparts (Figure S4C). To examine the func-
tional relevance of this p38 activation, we plated thymic endothe-
lial cells from mice treated with doxorubicin in the presence or
absence of a p38 inhibitor (Figure 5F). Strikingly, the addition
of a p38 inhibitor not only prevented IL-6 induction, but actually
reduced the level of secreted IL-6 to below the level in untreated
cells. To investigate whether this DNA damage-induced IL-6
release is a conserved characteristic of endothelial cells, we per-
formed similar experiments in human vascular endothelial cells
(HUVECs). Cultured HUVECs were treated with doxorubicin
and conditioned media was collected 24 hr after treatment.
Here, doxorubicin elicited a threefold increase in the amount of
secreted IL-6 (Figure 5G). This process was also dependent
upon p38 activity, as concurrent treatment of HUVECs with
doxorubicin and a p38 inhibitor blocked IL-6 induction (Figures
5F and 5H).
Cell-based studies have implicated the ATM checkpoint
kinase in senescence-associated secretory phenotypes (SASP)
(Rodier et al., 2009). To examine the relevance of ATM to endo-
thelial IL-6 release, we treated HUVECs with doxorubicin and an
ATM inhibitor (Figure 5H). Surprisingly, as opposed to blocking
cytokine secretion, ATM inhibition significantly increased the
level of endothelial IL-6 release. These data suggest that the
biology of acute cytokine release may be distinct from SASP.
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Figure 5. Endothelial Cells Secrete IL-6 and
Timp-1 in Response to DNA Damage in
a p38 MAP Kinase-Dependent Manner
(A and B) (A) IL-6 and (B) Timp-1 levels were quan-
tified by ELISA in conditioned media derived from
sorted thymic cell populations The data are repre-
sented as mean ± SEM (nR 3 independent exper-
iments). Values were normalized to the number of
cells sorted.
(C) A graph showing lymphoma cell survival in
response to 20nM doxorubicin, with or without
endothelial cell co-culture. Fold change in cell
number was assessed at 48 and 72 hr posttreat-
ment. The data are represented as mean ± SEM
(n = 6 independent experiments).
(D) A western blot for Bcl-XL levels in lymphoma
cells in the presence or absence of TCM for
24 hr. The blot is representative of three indepen-
dent experiments.
(E) A graph showing the results of a GFP competi-
tion assay in cells partially transduced with
a Bcl-XL shRNA or a control vector. Fold change
in GFP percentage was assessed 48 hr following
treatment with 20nM doxorubicin. The data are
represented as mean ± SEM (n = 3).
(F) A bar graph showing the amount of IL-6 in
conditioned media from endothelial cells sorted
from the thymus of untreated mice (n = 5), mice
treated with doxorubicin (n = 8) or mice treated
with doxorubicin plus 10 mm SB203580 (n = 4).
Values were normalized to cell number. The data
are represented as mean ± SEM.
(G) A graph showing the amount of IL-6 present in
conditioned media from untreated and treated
human vascular endothelial cells (HUVECs). The
data are represented as mean ± SEM (n = 3).
(H) A graph showing the amount of IL-6 present in
conditioned media from HUVECs 48 hr after treat-
ment with doxorubicin alone or doxorubicin plus
either 10 mm SB203580 or 10 mm KU55933. The
data are represented as mean ± SEM (n = 3).
See also Figure S4.Cytotoxic Chemotherapy Induces Senescence
in Thymic Stromal Cells In Vivo
Recent studies have shown that an autocrine IL-6 signaling
loop is induced upon oncogene activation and that this auto-
crine loop reinforces oncogene induced senescence (OIS)
(Coppe et al., 2008; Kuilman et al., 2008). This observation
led us to investigate whether IL-6 secretion in the thymus is
accompanied by drug-induced senescence. To determine
whether doxorubicin induces senescence in vivo, we harvested
the thymus and lymph nodes from mice 6 days following
treatment with doxorubicin. Tissues were frozen, sectionedCell 143, 355–366,and stained for b-Galactosidase activity –
a marker of cellular senescence (Dimri
et al., 1995). Tissues from untreated
mice showed no senescent cells (Fig-
ure 6A). In sharp contrast, b-Galactosi-
dase-positive cells were abundant in
the thymus, but not the lymph nodes,of doxorubicin-treated mice (Figure S5A). Notably, this ‘‘senes-
cent’’ state was transient, as b-Galactosidase positive cells
were no longer present at twelve days following treatment
(Figure S5B). While the mechanism underlying the transient
presence of senescent cells in this context is unclear, these
data are consistent with the recognition and removal of senes-
cent cells by the innate immune system (Krizhanovsky et al.,
2008; Xue et al., 2007). Thus, doxorubicin can elicit the acute
release of prosurvival cytokines from non-tumor cells in the
thymus, coincident with a more gradual induction of senes-
cence.October 29, 2010 ª2010 Elsevier Inc. 361
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Figure 6. Genotoxic Damage Promotes Cellular
Senescence in Thymic Stromal Cells and Subsequent
IL-6-Mediated Thymic Rebound
(A) b-galactosidase staining of normal and tumor-bearing
thymuses and lymph nodes in the presence or absence of
doxorubicin-induced DNA damage. Representative fields are
shown at 203 magnification.
(B) A graph showing relative thymic and splenic weight follow-
ing genotoxic damage in the presence and absence of IL-6.
Organ weights are shown as the ratio of individual irradiated
thymus or spleen weights relative to the average unirradiated
thymicor spleenweight for eachgenotype.Eachdot represents
an individual mouse, with a line demarcating themean for each
cohort. The data are represented as mean ± SEM.
See also Figure S5.To confirm that a similar ‘‘senescent’’ state also occurs in the
thymic tumor microenvironment, lymphoma-bearing mice were
treated with doxorubicin. Six days following treatment, mice
were sacrificed and tumors were harvested. Again, thymic tumor
sites showed the presence of disseminated senescent cells,
while the lymph nodes lacked any b-galactosidase positivity
(Figure 6A and Figure S5A). At least a component of this treat-
ment-induced senescent population was comprised of endothe-
lial cells, as purified CD31+/CD34+ cells showed senescent
phenotypes – including b–galactosidase activity (Figure S5C).
Notably, tumor-bearing thymuses and lymph nodes showed
similar numbers of macrophages and dendritic cells, suggesting
that the b-galactosidase positive cells in the thymus were
resident stromal cells as opposed to infiltrating immune cells
(Figure S5D).
IL-6 Modulates a General Response to DNA Damage
in the Thymus
The presence of a prosurvival secretory response in the thymus
following chemotherapy led us to investigate whether IL-6 is
involved more generally in stress-induced thymic homeostasis.
Whole body irradiation, such as that occurring prior to bone
marrow transplantation, induces thymocyte cell death, periph-
eral leucopenia and thymic involution. This acute wave of thymo-
cyte death is followed by an acute regrowth of the thymus,
termed ‘‘thymic rebound’’ (Delrez et al., 1978). To assess
whether IL-6 induced by DNA damage is similarly cytoprotective362 Cell 143, 355–366, October 29, 2010 ª2010 Elsevier Inc.in this setting, we irradiated wild-type and IL-6/
mice. 5 or 12 days later, all mice were sacrificed
and the spleen and thymus were harvested and
weighed. Thymic regrowth in IL-6/ mice was
significantly reduced when compared to wild-
type control mice (Figure 6B), while no difference
was seen in the spleen. Therefore, IL-6 secretion in
the thymus may be critical for thymic growth and
repopulation following diverse genotoxic stresses.
Genotoxic Damage Promotes Acute IL-6
Release and Chemoprotection in Human
Liver Cancer Cells
Previous descriptions of secretory phenotypes
have reported a gradual induction of cytokinerelease following the onset of stress-induced cellular senes-
cence. This suggests that the release of prosurvival cytokines
may not occur rapidly enough to impact chemotherapeutic
response. The finding that doxorubicin can induce an acute
secretory response led us to investigate whether IL-6 induction
might be relevant to therapeutic response in contexts other
than the thymic microenvironment. Recent reports have impli-
cated IL-6 as a major contributor to the pathogenesis of hepato-
cellular carcinoma (HCC) (Naugler et al., 2007; Wong et al.,
2009). In humans, activating mutations in gp130, the obligate
signal transducing subunit of the IL-6 receptor, have been
recently identified (Rebouissou et al., 2009). Additionally recent
expression profiling identified the presence of an IL-6 induced
transcriptional signature in the tumor stroma that is associated
with poor prognosis in hepatocellular carcinoma (Hoshida
et al., 2008).
We treated an HCC cell line, Focus cells, with doxorubicin -
a front-line therapy for HCC - and measured the levels of
secreted IL-6 after 24 hr. Consistent with our endothelial cell
data, IL-6 secretion was increased over 3-fold acutely following
treatment (Figure 7A). Notably, treated cells lacked any markers
of senescence at this time point, indicating that senescence is
not required for acute cytokine release. In contrast with endothe-
lial cells, IL-6 secretion could be partially inhibited by either a p38
or an ATM inhibitor (Figure 7B). Thus, pathway requirements for
acute secretory phenotypesmay be somewhat variable between
cell types.
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p<0.01p<0.01 Figure 7. DNA Damage Acutely Induces IL-
6 in Human Hepatocellular Carcinoma,
Promoting Both Cellular Survival and
Senescence
(A) IL-6 levels were quantified in conditioned
media derived from Focus cells treated with 200
nM doxorubicin for 24 hr. The data are repre-
sented as mean ± SEM (n = 3).
(B) A graph showing the amount of IL-6 present
in Focus cells 48 hr following treatment with either
SB203580 or KU55933, in the presence or
absence of doxorubicin. The data are represented
as mean ± SEM (n = 3).
(C) A graph showing the results of an acute cell
survival assay in which Focus cells were treated
with doxorubicin and increasing doses of Ag490,
as indicated, for 4 days. The data are represented
as mean ± SEM (n = 3 independent experiments).
(D) A colony formation assay showing Focus cells
that were treated with doxorubicin, Ag490 or both
for 24 hr before replating. Results are representa-
tive of three independent experiments.We then investigated whether inhibition of IL-6 signaling could
enhance doxorubicin-induced cell death in HCC cells. We
treated Focus cells with doxorubicin alone, Ag490 alone or
doxorubicin in combination with Ag490. Treatment with both
doxorubicin and Ag490 resulted in more apoptosis and fewer
surviving cells in acute survival assays than either single agent
alone (Figure 7C). The combination treatment of doxorubicin
and Ag490 was also more effective than single agent therapy
when measured in a colony formation assay (Figure 7D). These
data suggest that acute drug-induced IL-6 release is chemopro-
tective in HCC and may contribute to the intrinsic chemoresist-
ance of these tumors.
DISCUSSION
The persistence of minimal residual disease following anticancer
therapy is strongly correlated with decreased survival in patients
(Xenidis et al., 2009). However, the mechanisms by which cells
survive in select contexts following chemotherapy are unclear.
In amousemodel of Burkitt’s lymphoma, we show that a specific
anatomical location, the thymus, confers a potent cytoprotective
benefit to lymphoma cells treated with genotoxic chemotherapy.
This surviving cell population is functionally relevant to disease
progression, as ablation of the thymus prolongs both tumor
free survival and overall survival following treatment with chemo-
therapy.While the importance of the thymicmicroenvironment to
tumor cell survival in human malignancy remains unclear, we
expect that factors contributing to drug resistance at this site
may also underlie MRD persistence at analogous locations in
human cancers.Cell 143, 355–366,The establishment of the thymic pro-
survival microenvironment occurs, para-
doxically, as a response to genotoxic
chemotherapy. Specifically, prosurvival
chemokines and cytokines are acutely
released following DNA damage. Whilethe complete signaling network leading from a DNA damage
response to cytokine release remains unclear, it involves the
activation of stress responsive kinases – most notably the MAP
kinase p38. Thus, cells exposed to genotoxic damage in vivo
can engage well-described cell cycle arrest and apoptotic
programs, as well as a physiological stress response pathway
leading to survival signaling. Importantly, the resulting secretory
response occurs not in the tumor cells themselves, but in prox-
imal endothelial cells. Drug treated endothelial cells release
IL-6 and Timp-1, which promote the induction of Bcl-XL in prox-
imal lymphoma cells. As a result, proapoptotic signaling induced
by the direct action of chemotherapy on tumor cells is countered
by antiapoptotic signaling emanating from the treated vascular
compartment in the tumor microenvironment.
Recent literature has shown that the induction of oncogene-
induced cellular senescence elicits a secretory response (Coppe
et al., 2008; Kuilman et al., 2008). Here we find that IL-6 is
induced acutely following DNA damage, prior to the onset of
senescence. This difference between a prosurvival response
that occurs within one day of treatment and a SASP that is
detectable only after 3-4 days is critical. Chemotherapy-induced
cell death generally occurs with 48 hr of treatment. Thus, a SASP
simply cannot effectively alter treatment response, as it occurs
well after tumor cell death decisions are made. However, our
data does not preclude a role for senescence in overall tumor
survival following therapy. Given that significant levels of senes-
cence occur in the thymus days after doxorubicin treatment, it is
possible that elevated IL-6 levels are maintained through the
establishment of a SASP. Thus, acute cytokine release and
subsequent senescence-related secretory phenotypes mayOctober 29, 2010 ª2010 Elsevier Inc. 363
represent a general strategy to promote paracrine cell survival in
response to genotoxic stress in select microenvironments.
Secretory and inflammatory processes have been shown to be
critical for tissue repair and regeneration (Grivennikov et al.,
2009; Krizhanovsky et al., 2008). Thus, chemotherapy in the
thymic setting may activate physiological mechanisms of tissue
homeostasis. Consistent with this idea, the thymus is known to
engage prosurvival and growthmechanisms in response to other
cellular stresses. Following radiotherapy and subsequent thymic
atrophy (Muller-Hermelink et al., 1987), the thymus regrows and
replenishes the peripheral T cell population, leading to significant
thymic hyperplasia – even in adults with limited remaining thymic
tissue (Sfikakis et al., 2005). Factors that govern this process
have not been previously identified. Here we show that IL-6
modulates thymic recovery in response to DNA damage. This
suggests that lymphomas, and perhaps other malignancies,
can co-opt organ-specific prosurvival mechanisms.
Interestingly, serum IL-6 levels are elevated in many types of
cancer (Trikha et al., 2003), and high IL-6 levels are strongly
correlated with poor overall survival and accelerated disease
progression in a variety of cancers, including lymphomas
(Seymour et al., 1995). Furthermore, IL-6 levels are greatly
increased in metastatic disease versus non-metastatic disease
(Salgado et al., 2003). Consequently, stromal or tumor upregula-
tion of IL-6 may contribute to the intrinsic chemoresistance
commonly found in both primary and metastatic malignancies.
Additionally, tumor-directed inflammatory responses that result
in IL-6 release may similarly limit the efficacy of genotoxic
agents. These data demonstrate how both intrinsic genetic alter-
ations as well as chemoprotective microenvironments can play
decisive roles in the cellular response to genotoxic insults.
Thus, improved chemotherapeutic regimesmay require a combi-
nation of cytotoxic agents, which target tumor cells, and tar-
geted therapeutics that inhibit prosurvival signaling from the
tumor-adjacent cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Chemicals
Em-Myc;p19Arf/ mouse B cell lymphomas were cultured in B cell medium
(45% DMEM/45% IMDM/10% FBS, supplemented with 2 mM L-glutamine
and 5mM b-mercaptoethanol). g-irradiated NIH 3T3 cells were used as feeder
cells. Focus cells were cultured in MEM with 10% FBS. HUVEC cells were
cultured in Endothelial Cell Growth Medium 2 (Lonza). Doxorubicin, Jak Inhib-
itor 1 and Ag490 mCF3 were purchased from Calbiochem. SB203580 and
KU55933 were purchased from Tocris Bioscience. Gefitinib was purchased
from LC labs. For in vivo studies, Ag490 m-CF3 was dissolved in DMSO and
then diluted 3:2 in DMEM plus 10% FBS.
Conditioned Media
Conditioned media was made from mouse tissues 18 hr after doxorubicin
treatment. Conditioned media for viability assays and cytokine arrays was
derived from organs from 3–4 pooledmice, while media for ELISAs was gener-
ated from individual mice. All tissues were dissociated manually in B cell
media. Thymic, bone marrow and lymph node conditioned media were condi-
tioned for 6 hr at 37C. To isolate single-cell types from the thymus, tissue was
manual dissociated and washed two times in serum free DMEM, followed by
incubation for 1 hr at 37C with Liberase (Roche, 1.3 Wunsch units/mL) and
Dnase I (0.15 mg/mL). To aid in dissociation, samples were manually pipetted
at 15 min intervals. Single-cell populations were sorted using FITC conjugated
antibodies to the following cell surface markers: CD45, CD19, CD11b, CD11c,364 Cell 143, 355–366, October 29, 2010 ª2010 Elsevier Inc.MHC II, CD31/CD34 for T cells, B cells, macrophages, dendritic cells, epithelial
and endothelial cells, respectively. Cells were plated and allowed to condition
media for 48 hr at 37C and 5% CO2. All conditioned medias were cleared of
tissue and cells by centrifugation. All values shown for viability assays, ELISAs
and cytokine arrays are normalized to the weight of the dissected tissue or the
number of sorted cells. For the viability assays, conditioned medias were
diluted one to three. IL-6 ELISA kits were purchased from eBioscience. The
Timp-1 ELISA kit and mouse cytokine arrays were purchased from R&D
Biosystems.
In Vitro Viability, Competition, and Cell Growth Assays
For viability, competition and growth assays Em-Myc;p19Arf/ lymphoma
cells were split into replicate wells of z500,000 cells in 24-well plates
or z125,000 cells in a 48-well plate. Every 24 hr, cultured cells were resus-
pended by pipeting and half of the culture was replaced with fresh medium.
Viability and cell number were determined by propidium iodide exclusion.
For the competition assay, lymphoma cells were partially infectedwith the indi-
cated retroviruses. The fold change for the competition assay is calculated by
dividing the percentage of GFP positive lymphoma cells in the treated popula-
tion by the percentage in untreated populations. Murine Timp-1 was
purchased from R&D Biosystems and used at 100ng/mL. All other cytokines
were purchased from Peprotech and used at 10ng/mL. Jak Inhibitor 1 was
used at a final concentration of 500nM, and Gefitinib was used at a final
concentration of 3 mM.
In Vivo Response to Chemotherapy
All mice were purchased from Jackson Laboratory. For survival assays, 1 3
106 Em-Myc;p19Arf/ mouse lymphoma cells were injected by tail-vein injec-
tion into syngenic C57BL/6J, C57BL/6J IL-6/ or C57BL/6J Rag1/ mice.
Lymphoma burden was monitored by palpation of the axillary and brachial
lymph nodes. At the presentation of a substantial tumor burden (12–13 days
after injection), mice were treated with doxorubicin and/or Ag490 m-CF3.
Tumor free survival was monitored by palpation and in vivo GFP imaging using
a NightOwl imaging system (Berthold).
Thymic Rebound in Response to Radiation
Untreated 6 to 8 week old C57BL/6J or C57BL/6J IL-6/mice were sacrificed
to establish basal spleen and thymic weight. 6 to 8 week old C57BL/6J or
C57BL/6J IL-6/ mice were irradiated with 4 or 5 Gray. 5 or 12 days later
all mice were sacrificed and the spleen and thymus were weighed.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism4 software. Two-
tailed Student’s t tests were used, as indicated. Error bars represent mean ±
SEM. For comparison of survival curves, a Kaplan-Meier test was used.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
2010.09.043.
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